Karyopharm Therapeutics (KPTI) has opened Q1 2026 earnings season with revenue of about US$34.1 million in Q4 2025 and a basic EPS loss of US$5.71, providing a clear snapshot of a business still investing heavily for growth. Over recent quarters the company has seen revenue move between US$30.0 million and US$44.0 million, while basic EPS losses have ranged from roughly US$2.77 to US$5.71. This gives a tangible sense of how top line and per share results have been tracking into the latest print. With the stock at US$7.69, the key takeaway from these numbers is that margins remain under pressure and profitability is still some way from catching up with revenue potential.

See our full analysis for Karyopharm Therapeutics.

With the headline figures set, the next step is to see how they line up against the bullish and bearish narratives that have built around Karyopharm, and where the latest results either reinforce or challenge those stories.

US$196 million trailing loss keeps profitability distant

• Over the latest trailing twelve months, Karyopharm reported total revenue of US$146.1 million and a net loss of US$196.0 million, so the business is still spending meaningfully more than it brings in.
• Consensus narrative expects revenue growth to help earnings over time, yet the current net loss and negative net profit margin contrast with that, because:
  • Analysts expect revenue to grow at about 29.1% per year, but forecasts still do not point to profitability in the next three years.
  • Losses have reduced at roughly 10.3% per year over the past five years, which supports the view that the earnings trend is improving, even if the latest trailing loss remains large in absolute terms.

Low 1.2x P/S against peers’ 10.9x

• The stock trades on a P/S of roughly 1.2x, compared with around 10.9x for the broader US biotech industry and about 18.3x for peers. This means the market is valuing each dollar of Karyopharm revenue at a discount to many comparables.
• Bulls argue that faster revenue growth can justify a higher valuation multiple, but the current numbers also leave room for caution because:
  • Revenue across the last four reported quarters has stayed in a relatively tight band between US$30.0 million and US$44.0 million per quarter, so investors are still waiting for the higher top line that growth forecasts point to.
  • The trailing net loss of US$196.0 million and lack of a clear path to profitability in the next three years may explain why the market is keeping the P/S multiple well below peers despite those revenue growth expectations.

Analysts who back the more optimistic view see current P/S levels as a possible mismatch with future trial milestones and new indications, and you can see how they lay out that case in the 🐂 Karyopharm Therapeutics Bull Case.

Negative equity and dilution amplify bear concerns

• Risk analysis highlights negative shareholders’ equity and substantial share dilution over the past year, alongside recent insider selling and higher share price volatility compared with the broader US market.
• Bears focus heavily on these balance sheet and ownership signals, and the recent financials line up with several of their concerns because:
  • The trailing twelve month net loss of US$196.0 million, against revenue of US$146.1 million, points to ongoing cash needs that can feed further dilution if external funding is required.
  • Forecasts calling for continued losses over at least the next three years mean those capital structure pressures are not just historical issues but part of the current investment equation.

Skeptical investors lean on these figures when they question how long the company can fund losses without further dilution, and that argument is set out in more detail in the 🐻 Karyopharm Therapeutics Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Karyopharm Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both risks and rewards in play, the real question is how you weigh them for your own portfolio. To explore this further, take a closer look at the 2 key rewards and 5 important warning signs.

See What Else Is Out There

Karyopharm is carrying a trailing loss of US$196.0 million, negative equity and ongoing dilution concerns, so balance sheet strength is a key missing piece.

If you want ideas where financial footing looks firmer, check out the solid balance sheet and fundamentals stocks screener (45 results) now and compare companies with healthier balance sheets against Karyopharm.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.